Literature DB >> 17589489

Attaining a working archwire--which sequence?

Carlos Flores-Mir1.   

Abstract

DESIGN: This was a multicentre randomised controlled trial (RCT). INTERVENTION: Patients were treated in three centres and randomly allocated to one of three groups, as follows: group A used 0.016-inch nickel titanium (NiTi), 0.018x0.025-inch NiTi and 0.019x0.025-inch stainless steel (SS); group B used 0.016-inch NiTi, 0.016-inch SS, 0.020-inch SS and 0.019x0.025-inch SS; and group C used 0.016x0.022-inch copper-NiTi, 0.019x0.025-inch copper-NiTi and 0.019x0.025-inch SS. OUTCOME MEASURE: Outcome measures were patient discomfort at each archwire change and total discomfort for each archwire sequence, root resorption (root length) of an upper left central incisor (in mm), and time to reach an upper and lower working archwire (0.019x0.025-inch SS) in months, and also the number of visits.
RESULTS: There were no statistically significant differences between archwire sequences A, B or C in terms of patient discomfort (P>0.05) or root resorption (P 0.58). The number of visits required to reach a working archwire was greater for sequence B than for A (P 0.012) but this could not be explained by the increased number of archwires used in sequence B.
CONCLUSIONS: The archwire sequences investigated were not statistically significantly different in terms of patient discomfort and upper incisor root resorption. However, clinicians may choose sequence A to minimise the number of visits required to attain a working archwire.

Entities:  

Year:  2007        PMID: 17589489     DOI: 10.1038/sj.ebd.6400494

Source DB:  PubMed          Journal:  Evid Based Dent        ISSN: 1462-0049


  1 in total

1.  Evaluation of the alignment efficiency of nickel-titanium and copper-nickel-titanium archwires in patients undergoing orthodontic treatment over a 12-week period: A single-center, randomized controlled clinical trial.

Authors:  Burcu Aydın; Neslihan Ebru Şenışık; Özgür Koşkan
Journal:  Korean J Orthod       Date:  2018-04-20       Impact factor: 1.372

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.